Initiate a Phase 2 clinical trial of Auxora in acute kidney injury
Delivered after the deadline (9 days after the deadline)
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 22 Jan 2024
- Due
- 30 Jun 2024
- Delivered
- 9 Jul 2024
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“planned Phase 2 acute kidney injury (AKI) trial expected to begin in 1H 2024”
What we found
Evidence strength B What the grades mean
CalciMedica initiated the Phase 2 KOURAGE trial with first patient dosing on July 9, 2024, nine days after the stated 1H 2024 deadline of June 30, 2024.
-
B CalciMedica Announces First Patient Enrolled in Phase 2 KOURAGE Trial of Auxora in Severe Acute Kidney Injury (AKI) Company press release announcing first patient dosed in KOURAGE trial on July 9, 2024
Checked 21 Sep 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Language
- Expected (“expects”, “plans”)
How this entry was checked
- Commitment recordedRecorded from the company's filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you CalciMedica, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-CALC-000027 · Corrections policy